CorePharma is a pharmaceutical company dedicated to the contract development and manufacturing space. Founded in 1998 and headquartered in Middlesex, NJ, CorePharma has become a leading player in the CDMO space. CorePharma are experts in developing and manufacturing oral solid products on behalf of our clients. With the help of our 100,000+ square foot cGMP compliant facilities, 3 billion units a year capacity, remarkable equipment, and dedicated expertise to create high-quality products that meet regulatory requirements. CorePharma works with clients from the early stages of drug development all the way through to commercialization, providing a seamless transition from development to manufacturing. We provide a number of benefits to our clients; including access to specialized expertise, advanced technology, and state-of-the-art facilities. We support our clients throughout the development process with flexibility and scalability, allowing any of our clients to rapidly scale up or down their manufacturing operations as needed. CorePharma also places a strong emphasis on customer service, striving to build long-term partnerships with their customers by providing excellent service and support. We work closely with our customers to understand their unique needs and tailor their offerings to meet those needs. We are dedicated to improving the health and well-being of people around the world by providing safe, effective, and affordable medications to all. | CorePharma is a “Quality Driven + People Powered” US based contract development and manufacturing organization (CDMO) of high-quality pharmaceuticals across various therapeutic categories. Our focus is on providing end-to-end solutions from early-stage drug development through commercial launch and beyond. With an excellent regulatory inspection track record, CorePharma currently operates 5 state of the art, US FDA and DEA registered, development, analytical, clinical and commercial manufacturing and packaging facilities totaling 150,000 sqft and an annual capacity to produce 4 billion dosage units per year. With industry leading lead times, we can truly accelerate your timelines to get your project from the lab to the clinic to the patient. At CorePharma, we are committed to being your concept to commercial CDMO platform for success. | CorePharma is a leading U.S.-based contract development and manufacturing organization (CDMO), dedicated to delivering high-quality pharmaceuticals across diverse therapeutic categories. We provide comprehensive, end-to-end solutions—from early-stage drug development to commercial launch and beyond. With a proven track record of regulatory excellence, CorePharma operates 4 state-of-the-art, FDA- and DEA-registered facilities, spanning 150,000 square feet. Our advanced development, analytical, clinical, and commercial manufacturing and packaging capabilities support an annual production capacity of 5 billion dosage units. Backed by industry-leading lead times, we accelerate your journey from the lab to the clinic—and ultimately to the patient. At CorePharma, we are committed to being your concept to commercial CDMO platform for success.
Corealis Pharma Inc.
COREALIS Pharma is a private company offering formulation development and clinical supplies manufacturing services to pharmaceutical and biotech companies. Our state-of-the-art laboratories and manufacturing facilities allow our experts to successfully complete the most complex formulation development and clinical supply manufacturing mandates. COREALIS Pharma’s goal is to provide complete satisfaction to all clients by providing high-quality services and delivering compliant phase-appropriate drug products on time, every time. Formulation Development – COREALIS Pharma offers “turn-key projects”, ie performing the complete project development steps of a finished product. We can also take on specific projects and perform one or several phases of the product development process. We have a very flexible approach and pride ourselves in providing superior personalized services with fast project start-up. Clinical Suply Manufacturing – COREALIS Pharma offers clinical dosage manufacturing, release and stability testing, and packaging for clinical trials. Support during the submission to regulatory agencies and transfer of the products and processes to a large scale manufacturing site are also provided. All clinical manufacturing work is performed within COREALIS’s quality systems which are reviewed on a regular basis by Qualified Quality Persons. | COREALIS Pharma is a private company offering formulation development and clinical supplies manufacturing services to pharmaceutical and biotech companies. Our state-of-the-art laboratories and manufacturing facilities allow our experts to successfully complete the most complex formulation development and clinical supply manufacturing mandates. COREALIS Pharma’s goal is to provide complete satisfaction to all clients by providing high-quality services and delivering compliant phase-appropriate drug products on time, every time. | Corealis Pharma is a private company offering formulation development and clinical supplies manufacturing services to biotech and pharma. While our scientific and executive leadership has not changed since 2005, our capabilities are constantly evolving. Our state-of-the-art facilities allow our experts to complete the most complex formulation development and clinical supply manufacturing mandates for OSD products. We’re dedicated to providing complete satisfaction by ensuring high-quality services and delivering compliant, phase-appropriate formulation development and clinical supply on time, every time. | . | description/summary Corealis Pharma is a premier CDMO company, specializing in oral solid dosage (OSD) formulation development and phase I, II and early Phase III clinical supply manufacturing for trials worldwide. Located in Laval (Greater Montreal), Quebec, Canada, the state-of-the-art facilities, spanning over 60,000 sq ft, boasts modern technological solutions specializing in oral solid dosage (OSD) formulations. Specifically, Corealis provides: Pre-formulation & Solubility Enhancement: API characterization, solubility screening, and compatibility studies to set a solid foundation. Advanced Formulation Strategies: Spray drying, hot melt extrusion (HME), lipid-based systems, and particle engineering for stable, scalable products. Bioavailability Enhancement Technologies: Cutting-edge approaches to improve absorption, including cyclodextrin complexes and supersaturating formulations.
Comprehensive Cell Solutions
Founded in 2003 as a business unit of New York Blood Center Enterprises, Comprehensive Cell Solutions provides deep expertise in the development and manufacture of cell and gene therapies. CCS supports preclinical through commercial phase products with process and analytical development, GTP, and GMP facilities located in New York City, Houston, TX and Louisville, KY. Spanning cell sourcing and apheresis, cell isolation, manipulation, and cryopreservation, its unique Draw-to-Thaw™ portfolio is offered with the guidance of dedicated program management and regulatory support. Leveraging NYBCe’s expansive network, longstanding excellence in blood operations, related testing and research, CCS now serves some of the world’s leading pharmaceutical companies, innovative biotechnology organizations and academic medical centers on a mission to make advanced medicines accessible to more patients. Our Services: Cell Sourcing and Apheresis Process and Analytical Development GTP and GMP Fill/Finish Cryopreservation Project Management Regulatory Guidance | Founded in 2003 as a business unit of New York Blood Center Enterprises, Comprehensive Cell Solutions provides deep expertise in the development and manufacture of cell and gene therapies. CCS supports preclinical through phase I/II products with process and analytical development, GTP, and GMP facilities located in Rye, NY, Houston, TX and Louisville, KY. Spanning cell sourcing and apheresis, cell isolation, manipulation, and cryopreservation, its unique Draw-to-Thaw™ portfolio is offered with the guidance of dedicated program management and regulatory support. Leveraging NYBCe’s expansive network, longstanding excellence in blood operations, related testing and research, CCS serves some of the world’s leading pharmaceutical companies, innovative biotechnology organizations, and academic medical centers on a mission to make advanced medicines accessible to more patients.
City of Hope
City of Hope’s mission is to make hope a reality for all touched by cancer and diabetes. Founded in 1913, City of Hope has grown into one of the largest and most advanced cancer research and treatment organizations in the U.S., and one of the leading research centers for diabetes and other life-threatening illnesses. City of Hope research has been the basis for numerous breakthrough cancer medicines, as well as human synthetic insulin and monoclonal antibodies. With an independent, National Cancer Institute-designated comprehensive cancer center that is ranked top 5 in the nation for cancer care by U.S. News & World Report at its core, City of Hope’s uniquely integrated model spans cancer care, research and development, academics and training, and a broad philanthropy program that powers its work. City of Hope’s growing national system includes its Los Angeles campus, a network of clinical care locations across Southern California, a new cancer center in Orange County, California, and cancer treatment centers and outpatient facilities in the Atlanta, Chicago and Phoenix areas. City of Hope’s affiliated group of organizations includes Translational Genomics Research Institute and AccessHopeTM. For more information about City of Hope, follow us on Facebook, X, YouTube, Instagram and LinkedIn. | City of Hope’s mission is to deliver the cures of tomorrow to the people who need them today. Founded in 1913, City of Hope has grown into one of the largest cancer research and treatment organizations in the U.S. and one of the leading research centers for diabetes and other life-threatening illnesses. City of Hope research has been the basis for numerous breakthrough cancer medicines, as well as human synthetic insulin and monoclonal antibodies. With an independent, National Cancer Institute-designated comprehensive cancer center at its core, City of Hope brings a uniquely integrated model to patients spanning cancer care, research and development, academics and training, and innovation initiatives. City of Hope’s growing national system includes its Los Angeles campus, a network of clinical care locations across Southern California, a new cancer center in Orange County, California, and treatment facilities in Atlanta, Chicago and Phoenix. City of Hope’s affiliated group of organizations includes Translational Genomics Research Institute and AccessHopeTM. For more information about City of Hope, follow us on Facebook, Twitter, YouTube, Instagram and LinkedIn. | City of Hope’s mission is to make hope a reality for all touched by cancer and diabetes. Founded in 1913, City of Hope has grown into one of the largest cancer research and treatment organizations in the U.S. and one of the leading research centers for diabetes and other life-threatening illnesses. City of Hope research has been the basis for numerous breakthrough cancer medicines, as well as human synthetic insulin and monoclonal antibodies. With an independent, National Cancer Institute-designated comprehensive cancer center at its core, City of Hope brings a uniquely integrated model to patients spanning cancer care, research and development, academics and training, and innovation initiatives. City of Hope’s growing national system includes its Los Angeles campus, a network of clinical care locations across Southern California, a new cancer center in Orange County, California, and cancer treatment centers and outpatient facilities in the Atlanta, Chicago and Phoenix areas. City of Hope’s affiliated group of organizations includes Translational Genomics Research Institute and AccessHopeTM. For more information about City of Hope, follow us on Facebook, X, YouTube, Instagram and LinkedIn. | City of Hope is a world leader in cancer research, treatment and care. Since 1913, we have been dedicated to making a meaningful impact in the fight against life-threatening illnesses. Accordint o U.S. News and World Report, City of Hope is a top 5 cancer center in the United States and #1 in California. City of Hope’s Charitable Remainder Trust (CRT) program enables agricultural property owners to bypass capital gains tax when selling appreciated property. Additional benefits include creating a new source of lifetime income for the property owner and/or loved ones, a charitable income tax deduction and is a viable succession plan option for those who would like to downsize or retire from the property ownership business. In accordance with the IRS Code, a Charitable Remainder Trust (CRT) is a separate legal and charitable entity. When transferring property into a CRT first, the trust can sell the donated property and bypass capital gains tax at the time of the sale. After the donor’s lifetime, City of Hope will have access to the remaining funds for use towards research, making a difference in the lives of people with cancer, diabetes and other life-threatening illnesses.
Choose New Jersey
Choose New Jersey is a privately funded 501(c)(3) economic development organization with a mission to stimulate job creation and attract capital investment to New Jersey. Choose New Jersey markets New Jersey, both domestically and internationally, as the best place to grow a business in the United States. Knowledgeable, experienced staff, supported by a network of state agencies and private partners, provide free, confidential assistance to guide companies in establishing operations in New Jersey. By harnessing the power of business, labor, academic, and government leaders, Choose New Jersey enables growth across all sectors of the state’s economy, aspiring to build a stronger and more prosperous New Jersey for all. To learn more, visit choosenj.com. | Choose New Jersey is the State’s leading non-profit business attraction organization. We harness the collective power of New Jersey’s business, government, labor, and academic sectors to expand New Jersey’s economy. We work globally, using our marketing expertise, concierge business development services, deep knowledge of the State, and convening power in collaboration with State government to empower businesses, entrepreneurs, leaders, and innovators to make New Jersey their home. We are a privately funded 501(c)(3) organization. To learn more, visit choosenj.com. | x | Choose New Jersey is the state’s leading non-profit business attraction organization. We harness the collective power of New Jersey’s business, government, labor, and academic sectors to expand New Jersey’s economy. We work globally, using our marketing expertise, concierge business development services, deep knowledge of the state, and convening power, in collaboration with state government, to empower businesses, entrepreneurs, leaders, and innovators to make New Jersey their home.
China Chamber of International Commerce
China Chamber of International Commerce, or CCOIC, was established in 1988 with the approval of the State Council of the People’s Republic of China. Affiliated to China Council for the Promotion of International Trade (CCPIT), CCOIC is a nationwide chamber of commerce comprised of enterprises, groups and other business organizations that are engaged in international commercial activities in China. CCOIC also represents China in participating in the work of International Chamber of Commerce (ICC) with the name of ICC China. CCOIC adopts a membership system and its main responsibilities include: promoting economic and trade exchanges and cooperation between China and foreign countries; reflecting interest appeal of enterprises to international organizations and government departments of China and foreign countries on behalf of Chinese business community; participating in constitution and promotion of international trade rules; facilitating enterprises to participate in international competition and cooperation; safeguarding legitimate rights of its members, and actively advocating social responsibility and public welfare among business circles. By the end of 2021, CCOIC has 301,000 member enterprises, including most central SOEs, national financial institutions, a large number of well-known private enterprises and foreign-funded enterprises. CCOIC has become one of the most influential business associations in China. With the aim of building a hub-like chamber of commerce, CCOIC has institutional cooperation with other business associations from home and abroad, and provides services for its members and other enterprises including international exchange, industrial cooperation, legal advice, market information, exhibition planning, project investment and training. | China Chamber of International Commerce, or CCOIC, was established in 1988 with the approval of the State Council of the People’s Republic of China. Affiliated to China Council for the Promotion of International Trade (CCPIT), CCOIC is a nationwide chamber of commerce comprised of enterprises, groups and other business organizations that are engaged in international commercial activities in China. CCOIC also represents China in participating in the work of International Chamber of Commerce (ICC) with the name of ICC China. CCOIC adopts a membership system and its main responsibilities include: promoting economic and trade exchanges and cooperation between China and foreign countries; reflecting interest appeal of enterprises to international organizations and government departments of China and foreign countries on behalf of Chinese business community; participating in constitution and promotion of international trade rules; facilitating enterprises to participate in international competition and cooperation; safeguarding legitimate rights of its members, and actively advocating social responsibility and public welfare among business circles. Up to now, CCOIC has 351,000 member enterprises, including most central SOEs, national financial institutions, a large number of well-known private enterprises and foreign-funded enterprises. CCOIC has become one of the most influential business associations in China. With the aim of building a world-class chamber of commerce with Chinese characteristics, CCOIC has institutional cooperation with other business associations from home and abroad, and provides services for its members and other enterprises including international exchange, industrial cooperation, legal advice, market information, exhibition planning, project investment and training.
Chemveda Life Sciences
Chemveda is a growing chemistry-focused CRDMO based in Hyderabad, India, specializing in complex discovery and development-scale chemistry solutions. With over 16 years of experience, our team of over 500 chemists and manufacturing professionals provides global pharma, biotech, academia, agrochemical, and cosmeceutical players with high-quality Discovery Chemistry, Process R&D, and Custom Manufacturing services of drug substances, intermediates, and starting materials. Supported by a world-renowned scientific advisory board, including Profs. K.C. Nicolaou, Phil Baran, Jin-Quan Yu, and others, we built world-class chemistry capabilities that we can deploy to solve your problems efficiently.
ChemCon GmbH
ChemCon is a contract development and manufacturing partner for APIs and fine chemicals specialized in transferring R&D projects into fully cGMP-compliant manufacturing processes. Customers worldwide use our services to source APIs for clinical trials and/or commercial applications (i.e. orphan diseases), excipients, reference standards, and all kinds of other high-quality specialty chemicals. Our FDA-inspected facilities are optimized for the production of small to medium quantities. With multidisciplinary expertise we can meet your individual demands for small-molecule organic APIs, inorganic compounds including trace elements, polymers, and highly potent or controlled substances – all in full cGMP quality up to injection grade. Comprehensive in-house analytics, stability studies, documentation, and regulatory support complete our services. ChemCon can look back on an outstanding inspection history by both the FDA and European health authorities. | ChemCon is a contract development and manufacturing partner for APIs and fine chemicals specialized in transferring R&D projects into fully cGMP-compliant manufacturing processes. Customers worldwide use our services to source APIs for clinical trials and/or commercial applications (i.e. orphan diseases), excipients, reference standards, and all kinds of other high-quality specialty chemicals. Our FDA-inspected facilities are optimized for the production of small to medium quantities. With multidisciplinary expertise we can meet your individual demands for small-molecule organic APIs, inorganic compounds including trace elements, polymers, and highly potent or controlled substances – all in full cGMP quality up to injection grade. Comprehensive in-house analytics, stability studies, documentation, and regulatory support complete our services. ChemCon can look back on an outstanding inspection history both by the FDA and European health authorities. | ChemCon is a globally recognized partner for the development and manufacturing of active pharmaceutical ingredients (APIs) and fine chemicals. As a contract development and manufacturing organization (CDMO), ChemCon specializes in transferring research and development projects into fully cGMP-compliant manufacturing processes. Our company supplies customers worldwide with high-quality chemical products for clinical trials, commercial applications (including orphan drugs), pharmaceutical excipients, reference standards, and a broad range of other specialty chemicals. In addition to our custom manufacturing services, we also offer a selection of readily available products to meet immediate customer needs. Our Expertise ChemCon’s strength lies in the combination of chemical expertise, regulatory knowledge, and flexible production capabilities. Our multidisciplinary experience enables us to meet the unique requirements of our customers. Our portfolio includes small-molecule organic APIs, inorganic compounds, polymers, as well as highly potent or controlled substances – all manufactured in full cGMP quality up to injection grade. FDA-Inspected Manufacturing Facilities Our state-of-the-art, FDA-inspected manufacturing facilities are specifically optimized for small to medium-scale production. With this focus, we enable efficient, high-quality, and flexible production tailored to our customers’ needs. ChemCon has an outstanding inspection history with both the FDA and European health authorities. Versatile Manufacturing Processes Our production capabilities cover a wide range of chemical processes and technologies. Our expertise includes: • Organic Synthesis: Production of small-molecule APIs, organometallics, and polymer-based compounds. • Inorganic Chemistry: Manufacturing of metal salts, trace elements, radiolabeled compounds, and inorganic specialty chemicals. • Polymeric Chemistry: Development and synthesis of functional polymers for pharmaceutical and industrial applications. • Highly Potent Substances: Production of highly potent APIs (HPAPIs) under strict safety and cGMP conditions. • Controlled Substances: Manufacturing and handling of APIs subject to stringent regulatory requirements. Comprehensive Analytical Services In addition to manufacturing, ChemCon provides extensive in-house analytical services. Our analytical capabilities include: • Structural elucidation and purity determination • Stability studies following ICH guidelines • Method development and validation • Release and in-process controls These services ensure that our products meet the highest quality standards and comply with all regulatory requirements. Regulatory Support and Documentation ChemCon offers extensive regulatory support to its customers. Our experienced team assists with the preparation and maintenance of: • Registration dossiers (CMC documentation) • Drug Master Files (DMFs) • Manufacturing dossiers for clinical trials and market products • Regulatory communication and audit support Flexible and Tailored Solutions Our philosophy is based on flexibility and a collaborative partnership with our customers. We understand that every project is unique and therefore offer customized solutions for specific challenges. • Startups & Biotechs: Support in the development of new drugs and seamless transition from R&D to clinical manufacturing. • Pharmaceutical Companies: Supply of APIs for commercial products, optimization of existing manufacturing processes, and second-sourcing opportunities. • Universities & Research Institutions: Synthesis and supply of complex specialty chemicals for innovative research projects. Sustainability and Responsibility ChemCon is aware of its responsibility toward the environment and society. We focus on sustainable manufacturing practices, resource conservation, and continuous improvement of our environmental footprint. Our production is conducted in strict compliance with safety and environmental regulations. Extensive Experience and Excellence With more than two decades of experience in the chemical and pharmaceutical industry, ChemCon has established itself as a reliable partner. Our combination of scientific expertise, regulatory knowledge, and customer-oriented service makes us the first choice for companies that demand the highest quality and flexibility. Contact us to learn more about how we can support your project!
Charles River
Charles River is a global preclinical oncology CRO delivering end to end oncology and immuno oncology drug discovery, from target identification and validation through IND enabling and clinical. We partner with academic, biotechnology, and pharmaceutical companies to advance innovative cancer therapies. In 2025, Charles River supported 87% of FDA-approved oncology therapies, including first-in-class and best-in-class drugs. Our capabilities span small molecules, biologics, antibodies, antibody drug conjugates (ADCs), immunotherapies, checkpoint inhibitors, cell therapies, and gene therapies. Our research model (RMS) portfolio includes immunodeficient mice and rats, PBMC and CD34+ humanized mouse models, end-to-end support from colony management for Genetically Engineered Model (GEM), including transgenic model generation and breeding, to vivarium rental or customizable onsite services (staffing, consulting, training), and CRADL® support in global biohubs. Our oncology platforms include 1,700+ xenograft models (PDX, CDX, syngeneic, humanized), covering 45+ cancer indications across solid tumors, hematologic, and pediatric cancers. Integrated in vitro, ex vivo, NAMs and 3D tumor models—including organoids, tumoroids, and tissue microarrays (TMAs)- support efficacy, PK/PD, biomarker, and translational decision making. Multi omics, AI enabled analytics, and strategic CMC/CDMO capabilities help teams plan manufacturing earlier, strengthen regulatory readiness, improve study design, reduce risk, and accelerate candidate to patients. Learn more at criver.com/cancer-research-annual-meeting-2026 | Charles River has supported researchers in advancing ocular therapies for more than two decades, with a comprehensive suite of capabilities designed to meet your program needs. We help you progress small molecules, biologics, gene and cell therapies, and implantable devices from concept to clinic with confidence. Our team provides rigorous efficacy, distribution, and safety assessments supported by state-of-the-art imaging, functional evaluations, and New Approach Methodologies (NAMs) to help you improve predictability and generate high-quality data for global regulatory submissions. We also assess the ocular effects of systemic compounds for non-ocular indications, helping you refine study design, manage timelines and resources, and reduce animal use. We are committed to partnering with you at every stage to help bring meaningful treatments to patients worldwide because every moment matters. | Charles River provides essential products and services to support pharmaceutical and biotechnology companies, government agencies, and leading academic institutions worldwide in accelerating research and drug development. As a leader in scientific innovation, we are deeply committed to pioneering alternative methods that drive discovery while reducing reliance on traditional models. By embracing cutting-edge technologies and forward-thinking approaches, we enhance preclinical and clinical research. Our dedicated employees focus on delivering precisely what our clients need to improve, innovate, and expedite the discovery, early-stage development, and safe manufacture of new therapies for patients—because every moment matters. Learn more at www.criver.com. | Charles River is committed to helping companies like yours get your product to market safely and efficiently. Whether you’re still in development or already manufacturing, our Safety Assessment and Microbial Solutions services provide state-of-the-art technology and expert regulatory advice that will help you anticipate challenges, avoid roadblocks, and make better decisions.
Cellex Cell Professionals
Cellex is an end-to-end CDMO based in Cologne, Germany with 10+ years’ experience in manufacturing autologous & allogenic cell and gene therapy (CGT) products. We support customers from preclinical development stages through clinical manufacturing to commercialization. Currently, Cellex is manufacturing several final drug products (FDPs) and cellular intermediates (ITMs) including commercial products. In addition, Cellex offers customized starting materials from healthy donors and patients affected by specific conditions for research, clinical and commercial purposes as well as GDP-compliant logistics services for cellular materials. | Cellex is a European-based end-to-end CDMO with deep expertise in the development and GMP manufacturing of autologous and allogeneic cell and gene therapy (CGT) products. With a demonstrated GMP track record of more than 20 years, Cellex supports partners from preclinical development through clinical manufacturing to commercialization, serving top 10 pharma companies, leading biotech companies, innovative start-ups, and academic centers worldwide. Cellex operates more than 26,500 sqft of GMP manufacturing facilities and holds multiple manufacturing licenses covering cellular intermediates and final drug products. The company is involved in the manufacture of three approved CAR-T therapies and has produced over 9,000 CGT/ATMP batches. Through its own apheresis center and donor database, Cellex has performed more than 50,000 cell collections for CGT and stem cell transplantation, and provides a broad portfolio of starting materials – including leukopaks, mobilized leukopaks, bone marrow, and whole blood – from both healthy donors and patients affected by specific diseases, for R&D, clinical, and commercial use. All collections are performed under GMP conditions and supplied globally. EU QP services, consulting, and GMP audits of apheresis centers worldwide complement Cellex’s offering, which is characterized by scientific expertise, quality, and flexibility.